News & Updates
Filter by Specialty:

Transcutaneous electrical acustimulation effective in IBS with constipation
Patients with irritable bowel syndrome (IBS) and constipation (IBS-C) can improve their symptoms by undergoing transcutaneous electrical acustimulation (TEA), suggests a study. TEA speeds up colon transit and reduces rectal sensation, which is potentially mediated by using the autonomic mechanisms.
Transcutaneous electrical acustimulation effective in IBS with constipation
30 Sep 2022
Coeliac disease bidirectionally linked to IBD
A two-way association exists between coeliac disease (CeD) diagnosis and inflammatory bowel disease, which demands attention in the initial assessment and follow-up of such conditions, according to a study. Regardless of temporal sequence, this co-occurrence indicates a shared aetiology.
Coeliac disease bidirectionally linked to IBD
30 Sep 2022
Secondary kidney stones: to remove or not?
Pre-emptive removal of secondary* kidney stones during surgery to remove primary** stones led to fewer relapses and a similar number of emergency-department (ED) visits related to the surgery compared with leaving the secondary stones in place, a study suggests.
Secondary kidney stones: to remove or not?
30 Sep 2022
Brolucizumab for neovascular age-related macular degeneration holds up in real world
The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.
Brolucizumab for neovascular age-related macular degeneration holds up in real world
30 Sep 2022
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022
Ruxolitinib cream achieves durable itch-free state in atopic dermatitis
Among adults and adolescents with atopic dermatitis (AD), ruxolitinib cream helps sustainably improve itching, reports a recent analysis.
Ruxolitinib cream achieves durable itch-free state in atopic dermatitis
29 Sep 2022
SGLT2 inhibitors potentially protective against dry eye disease
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
SGLT2 inhibitors potentially protective against dry eye disease
29 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.